Healthcare Dive reports that US provider groups are pressing the Food and Drug Administration to make technology companies, rather than doctors, accountable for the safety and performance of generative AI-powered medical devices. They argue that developers are best placed to assess these tools.
This move could change how risk and responsibility are assigned in the use of AI in healthcare. It matters for healthcare and pharma leaders, as new liability rules could affect procurement, compliance, and partnerships with technology vendors.
